Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Coinbase Q1 2026 Earnings Miss Sends COIN Stock Lower Amid Crypto Market Slump 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
CAMBRIDGE, Mass., April 26, 2018 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, May 3, 2018, at 5:00 p.m. ET to discuss a corporate update and results for the first quarter of 2018.
To access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 6079429. A live webcast of the presentation will be available on the Investors & Media section of the Editas website.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Contacts
Media:
Cristi Barnett
(617) 401-0113
[email protected]
Investors:
Mark Mullikin
(617) 401-9083
[email protected]
